Semenov A V, Ostankova Yu V, Faizullaev Kh N, Kazakova E I, Kozlov A V, Musabaev E I, Totolyan Areg A
Zh Mikrobiol Epidemiol Immunobiol. 2016 Sep(5):43-49.
Evaluate significance of covalently closed circular DNA of hepatitis B virus as a marker for detection of occult viral hepatitis B in Uzbekistan population with hepatitis of various genesis.
Blood plasma and liver biopsy from 39 patients with different severity levels of liver fibrosis and cirrhosis served as study material. HBV covalently closed circular DNA detection was carried out according to Pollicino T et al. (2004).
Covalently closed circu- lar DNA of hepatitis B virus was detected in 82% of samples, including in 54.5% of patients with chronic viral hepatitis C (CVHC) and in 100% of patients with hepatitis of unknown etiology. Quantitative evaluation of content of covalently closed circular DNA of hepatitis B virus in liver tissue in patients with CVHB has shown an average of 2.5 copies of HBV genome as ccc DNA per cell, in patients with CVHB + D an average of 0.7 copies/cell, in patients with co-infection by HCV and HBV - 0.5 copies/cell, in patients with CVHC an average of 0.12 copies/cell, and in patients with cryptogenic hepatitis - 0.2 copies/cell.
Detection of HBV DNA is a complex problem for effective laboratory diagnostics of hepatitis. Detection of HBV ccc DNA as a marker of occult hepatitis B in patients with CVHC and patients with hepatitis of unclear etiol- ogy is an. important factor for diagnostics, selection of adequate therapy, prognosis of disease outcome and prevention of development of severe liver diseases.
评估乙型肝炎病毒共价闭合环状DNA作为乌兹别克斯坦不同病因肝炎患者隐匿性乙型肝炎检测标志物的意义。
选取39例肝纤维化和肝硬化严重程度不同的患者的血浆和肝组织活检标本作为研究材料。根据波利奇诺·T等人(2004年)的方法进行乙型肝炎病毒共价闭合环状DNA检测。
在82%的样本中检测到乙型肝炎病毒共价闭合环状DNA,其中包括54.5%的慢性丙型病毒性肝炎(CVHC)患者和100%病因不明的肝炎患者。对慢性乙型肝炎(CVHB)患者肝组织中乙型肝炎病毒共价闭合环状DNA含量的定量评估显示,平均每细胞有2.5个HBV基因组拷贝作为cccDNA,CVHB+D患者平均每细胞0.7个拷贝,丙型肝炎病毒和乙型肝炎病毒合并感染患者平均每细胞0.5个拷贝,CVHC患者平均每细胞0.12个拷贝,隐源性肝炎患者平均每细胞0.2个拷贝。
检测HBV DNA是肝炎有效实验室诊断中的一个复杂问题。检测CVHC患者和病因不明的肝炎患者中作为隐匿性乙型肝炎标志物的HBV cccDNA是诊断、选择适当治疗、疾病预后以及预防严重肝脏疾病发生的重要因素。